Design Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Design Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-06-30 was 58.09K shares.
- Design Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-03-31 was 55.84K shares, a 289.45% increase year-over-year.
- Design Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-12-31 was 41.97K shares, a 363.97% increase year-over-year.
- Design Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-09-30 was 15.63K shares, a 1427.96% increase year-over-year.
- Design Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 71.93K shares, a 93.72% increase from fiscal 2024.
- Design Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 37.13K shares, a 91.64% decline from fiscal 2023.
- Design Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 444.40K shares, a 96.52% increase from fiscal 2022.
- Design Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 226.13K shares, a 326.87% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2026-06-30 | 58.09K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | 171.52K shares derived: sum of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | 55.84K shares 10-Q · filed 2026-04-28 | 113.43K shares derived: sum of 4 quarters · filed 2026-04-28 |
| 2025-12-31 | 41.97K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | 71.93K shares 10-K · filed 2026-03-09 |
| 2025-09-30 | 15.63K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | 39.01K shares derived: sum of 4 quarters · filed 2025-11-05 |
| 2025-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | 24.41K shares derived: sum of 4 quarters · filed 2025-08-07 |
| 2025-03-31 | 14.34K shares 10-Q · filed 2025-05-07 | 30.80K shares derived: sum of 4 quarters · filed 2025-05-07 |
| 2024-12-31 | 9.04K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | 37.13K shares 10-K · filed 2025-03-10 |
| 2024-09-30 | 1.02K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | 451.65K shares derived: sum of 4 quarters · filed 2024-11-07 |
| 2024-06-30 | 6.39K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-05 | 463.67K shares derived: sum of 4 quarters · filed 2024-08-05 |
| 2024-03-31 | 20.67K shares 10-Q · filed 2024-05-08 | 462.83K shares derived: sum of 4 quarters · filed 2024-05-08 |
| 2023-12-31 | 423.57K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | 444.40K shares 10-K · filed 2024-03-19 |
| 2023-09-30 | 13.04K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | 42.85K shares derived: sum of 4 quarters · filed 2024-03-19 |
| 2023-06-30 | 5.56K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | 131.95K shares derived: sum of 4 quarters · filed 2024-03-19 |
| 2023-03-31 | 2.24K shares 10-Q · filed 2023-05-09 | 128.44K shares derived: sum of 4 quarters · filed 2024-03-19 |
| 2022-12-31 | 22.02K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | 226.13K shares 10-K · filed 2024-03-19 |
| 2022-09-30 | 102.14K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | |
| 2022-06-30 | 2.04K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | |
| 2022-03-31 | 99.93K shares 10-Q · filed 2022-05-09 | |
| 2021-12-31 | 52.97K shares 10-K · filed 2023-03-14 | |
| 2020-12-31 | 153.37K shares 10-K · filed 2022-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |